Immunogenicity of high-dose recombinant influenza vaccine versus standard-dose egg-grown and cell-grown vaccines among frequently and infrequently vaccinated young adults in Singapore: a randomised, controlled, double-blind, single-centre, phase 4 clinical trial
The Lancet Infectious Diseases·
- DOI
- 10.1016/s1473-3099(26)00062-9
- PMID
- 41936374
- PMCID
- —
- OpenAlex
- W7148256730
- Study type
- Randomised controlled trial
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Findings address whether enhanced antigen dose or non-egg production platforms can improve immunogenicity against A(H3N2) strains, which have been associated with reduced effectiveness of egg-derived vaccines.
Structured evidence summary
Research question
The trial compared antibody responses to high-dose recombinant, standard-dose cell-grown, and standard-dose egg-grown quadrivalent influenza vaccines among adults with differing recent vaccination histories.
Study design
A randomised, controlled, double-blind, single-centre phase 4 clinical trial with 1:1:1 allocation to three vaccine groups and stratification by prior vaccination frequency.
Population and setting
366 adults aged 21-49 years, enrolled at the National Centre for Infectious Conditions in Singapore between October 2022 and March 2023, with per-protocol analysis on 359 participants; no immunocompromising conditions.
Main findings
Post-vaccination geometric mean titres against cell-grown A(H3N2) were approximately 2.9-fold higher with high-dose recombinant vaccine than with cell-grown comparator, and antibody responses did not appear to differ between frequent and infrequent vaccinees. Specific numerical estimates are partially truncated in the supplied abstract; further detail requires the original paper.
Public-health relevance
Findings address whether enhanced antigen dose or non-egg production platforms can improve immunogenicity against A(H3N2) strains, which have been associated with reduced effectiveness of egg-derived vaccines.
Important limitations
The supplied abstract does not list explicit limitations; the summary is constrained to single-article abstract and metadata. Single-centre design in young adults, single-season antibody endpoints, and unmeasured clinical effectiveness outcomes are not described in the abstract but should be verified in the full paper.
GIDS interpretation
The study is discoverable in bibliographic indexes under influenza vaccination research conducted in Singapore; no claim can be made linking its findings to any live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 10 auditable classifier relationships to diseases, places, topics, and study design.